Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2004 2
2005 1
2006 1
2010 2
2011 1
2015 1
2017 2
2018 1
2019 1
2020 3
2021 4
2022 2
Text availability
Article attribute
Article type
Publication date

Search Results

18 results
Results by year
Filters applied: . Clear all
Page 1
Induction therapy with the selective interleukin-23 inhibitor risankizumab in patients with moderate-to-severe Crohn's disease: a randomised, double-blind, placebo-controlled phase 2 study.
Feagan BG, Sandborn WJ, D'Haens G, Panés J, Kaser A, Ferrante M, Louis E, Franchimont D, Dewit O, Seidler U, Kim KJ, Neurath MF, Schreiber S, Scholl P, Pamulapati C, Lalovic B, Visvanathan S, Padula SJ, Herichova I, Soaita A, Hall DB, Böcher WO. Feagan BG, et al. Among authors: lalovic b. Lancet. 2017 Apr 29;389(10080):1699-1709. doi: 10.1016/S0140-6736(17)30570-6. Epub 2017 Apr 12. Lancet. 2017. PMID: 28411872 Free article. Clinical Trial.
Psoriatic skin molecular and histopathologic profiles after treatment with risankizumab versus ustekinumab.
Visvanathan S, Baum P, Vinisko R, Schmid R, Flack M, Lalovic B, Kleiner O, Fuentes-Duculan J, Garcet S, Davis JW, Grebe KM, Fine JS, Padula SJ, Krueger JG. Visvanathan S, et al. Among authors: lalovic b. J Allergy Clin Immunol. 2019 Jun;143(6):2158-2169. doi: 10.1016/j.jaci.2018.11.042. Epub 2018 Dec 20. J Allergy Clin Immunol. 2019. PMID: 30578873 Free article. Clinical Trial.
Evaluation of the CYP3A and CYP2B6 Drug-Drug Interaction Potential of Lemborexant.
Landry I, Aluri J, Nakai K, Hall N, Miyajima Y, Ueno T, Dayal S, Filippov G, Lalovic B, Moline M, Reyderman L. Landry I, et al. Among authors: lalovic b. Clin Pharmacol Drug Dev. 2021 Jun;10(6):681-690. doi: 10.1002/cpdd.915. Epub 2021 Jan 17. Clin Pharmacol Drug Dev. 2021. PMID: 33455055 Free PMC article. Clinical Trial.
Pharmacokinetics, Pharmacodynamics, and Safety of the Dual Orexin Receptor Antagonist Lemborexant: Findings From Single-Dose and Multiple-Ascending-Dose Phase 1 Studies in Healthy Adults.
Landry I, Nakai K, Ferry J, Aluri J, Hall N, Lalovic B, Moline ML. Landry I, et al. Among authors: lalovic b. Clin Pharmacol Drug Dev. 2021 Feb;10(2):153-165. doi: 10.1002/cpdd.817. Epub 2020 May 28. Clin Pharmacol Drug Dev. 2021. PMID: 32468649 Free PMC article. Clinical Trial.
Risk-Based Pharmacokinetic and Drug-Drug Interaction Characterization of Antibody-Drug Conjugates in Oncology Clinical Development: An International Consortium for Innovation and Quality in Pharmaceutical Development Perspective.
Li C, Menon R, Walles M, Singh R, Upreti VV, Brackman D, Lee AJ, Endres CJ, Kumar S, Zhang D, Barletta F, Suri A, Hainzl D, Liao KH, Lalovic B, Beaumont M, Zuo P, Mayer AP, Wei D. Li C, et al. Among authors: lalovic b. Clin Pharmacol Ther. 2022 Oct;112(4):754-769. doi: 10.1002/cpt.2448. Epub 2021 Nov 23. Clin Pharmacol Ther. 2022. PMID: 34657311
18 results